Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENTX 
Entera Bio Ltd (ENTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ENTX (1-star) is a SELL. SELL since 1 days. Simulated Profits (-14.08%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -5.42% | Avg. Invested days 38 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 83.11M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 1 | Beta 1.69 | 52 Weeks Range 1.50 - 2.79 | Updated Date 09/16/2025 |
52 Weeks Range 1.50 - 2.79 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.26 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -6378.92% |
Management Effectiveness
Return on Assets (TTM) -44.56% | Return on Equity (TTM) -82.22% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 72452353 | Price to Sales(TTM) 500.65 |
Enterprise Value 72452353 | Price to Sales(TTM) 500.65 | ||
Enterprise Value to Revenue 439.21 | Enterprise Value to EBITDA -1.52 | Shares Outstanding 45663400 | Shares Floating 28765647 |
Shares Outstanding 45663400 | Shares Floating 28765647 | ||
Percent Insiders 24.31 | Percent Institutions 22.36 |
Upturn AI SWOT
Entera Bio Ltd
Company Overview
History and Background
Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in areas with significant unmet medical need, particularly osteoporosis and hypoparathyroidism. Founded to advance oral delivery technology for peptide and protein-based drugs.
Core Business Areas
- Oral Delivery Technology: Develops and utilizes an oral drug delivery platform based on modified amino acids to enable oral administration of large molecules.
- Osteoporosis Program: Developing EB613 (Oral PTH (1-34)) as a potential oral treatment for osteoporosis.
- Hypoparathyroidism Program: Exploring the use of oral PTH for treatment of hypoparathyroidism.
Leadership and Structure
Key executives include Spiros Jamas (CEO). The company has a board of directors overseeing strategic direction and corporate governance.
Top Products and Market Share
Key Offerings
- EB613 (Oral PTH (1-34)): Entera Bio's lead product candidate, an oral formulation of parathyroid hormone (PTH) (1-34) for the treatment of osteoporosis. Currently in clinical development. Market share is currently 0 as it is not approved. Competitors: Injectable PTH therapies like Eli Lilly's Forteo and Amgen's Prolia, as well as bisphosphonates such as alendronate (Fosamax).
- Oral PTH for Hypoparathyroidism: An orally delivered PTH formulation being explored for the treatment of hypoparathyroidism. Market share is currently 0 as it is not approved. Competitors: Injectable PTH therapies like Natpara (Takeda).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with significant investment in research and development of new therapies. The oral drug delivery market is expanding, driven by patient preference and convenience.
Positioning
Entera Bio is positioned as an innovator in oral delivery of large molecules, targeting osteoporosis and hypoparathyroidism with its oral PTH program. Competitive advantages include its proprietary oral delivery technology.
Total Addressable Market (TAM)
The osteoporosis market is estimated in the billions of dollars. The hypoparathyroidism market is smaller, but still represents a significant commercial opportunity. Entera Bio is positioned to capture a portion of these markets if its products are approved.
Upturn SWOT Analysis
Strengths
- Proprietary oral drug delivery technology
- Potential to replace injectable therapies with oral alternatives
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Clinical development risk
- Dependence on successful clinical trial outcomes
- Limited financial resources
- Competition from established therapies
Opportunities
- Growing demand for oral drug delivery
- Potential partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results driving investor confidence
Threats
- Failure to achieve positive clinical trial results
- Regulatory hurdles and delays
- Competition from new therapies and technologies
- Patent infringement or invalidity
Competitors and Market Share
Key Competitors
- LLY
- AMGN
- TAK
Competitive Landscape
Entera Bio's oral delivery technology provides a potential advantage over injectable therapies. However, the company faces competition from established pharmaceutical companies with significant resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited due to the company being in the clinical development stage.
Future Projections: Future growth depends on the successful development and commercialization of EB613 and other pipeline products. Analyst estimates vary depending on clinical trial progress and regulatory outlook.
Recent Initiatives: Focus on advancing EB613 through clinical trials, exploring partnerships, and securing financing.
Summary
Entera Bio is a clinical-stage biopharmaceutical company with a novel oral drug delivery technology. The company's success hinges on the successful development and commercialization of its lead product, EB613, for osteoporosis. While its oral delivery technology offers a potential advantage, Entera Bio faces significant clinical and regulatory hurdles. Financial health and strategic partnerships will be crucial for future success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Entera Bio Ltd. SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Entera Bio Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-06-28 | CEO & Director Ms. Miranda J. Toledano M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 19 | Website https://www.enterabio.com |
Full time employees 19 | Website https://www.enterabio.com | ||
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.